Adult Plaque Psoriasis (≥6 years, moderate-to-severe)
Yes
Yes
Adult Ankylosing Spondylitis
Yes
Yes
Adult Non-radiographic Axial Spondyloarthritis
Yes
Yes
Pediatric Enthesitis-Related Arthritis
No
Yes (≥4 years, ≥15 kg)
Adult Hidradenitis Suppurativa
No
Yes
Coverage
Add insurance carrier above to get more details about the coverage for each medication
dosing
Adult PsA - Dosing
160 mg (two 80 mg injections) at Week 0, then 80 mg every 4 weeks (no higher dose option specified)
Subcutaneous: 150 mg at Weeks 0, 1, 2, 3, and 4, then 150 mg every 4 weeks OR 150 mg every 4 weeks (without loading); 300 mg every 4 weeks if continued active PsA
Adult PsA with Coexistent Moderate-to-Severe PsO
Use adult plaque psoriasis dosing regimen ((160 mg at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks)
Use plaque psoriasis dosing regimen (300 mg at Weeks 0, 1, 2, 3, and 4, then 300mg every 4 weeks)
Adult PsA - Intravenous Option
Not available
With loading: 6 mg/kg at Week 0, then 1.75 mg/kg every 4 weeks (max 300 mg per infusion); Without loading: 1.75 mg/kg every 4 weeks
Pediatric PsA (2+ years, ≥15 kg)
Not approved
≥15 kg to <50 kg: 75 mg at Weeks 0, 1, 2, 3, 4, then every 4 weeks; ≥50 kg: 150 mg at Weeks 0, 1, 2, 3, 4, then every 4 weeks
Administration
Adults: Subcutaneous injection only
Adults: Subcutaneous injection or intravenous infusion; Pediatric: Subcutaneous injection only
pharmacology
Mechanism of Action
Humanized IgG4 monoclonal antibody that selectively binds IL-17A
Human IgG1 monoclonal antibody that selectively binds IL-17A
Half-life
Mean half-life: 13 days
Mean half-life: 22-31 days
Immunogenicity
PsA Population: 11% developed anti-drug antibodies, 8% had confirmed neutralizing antibodies (up to 52 weeks)
Across all populations: Less than 1% developed anti-drug antibodies, approximately 8% had neutralizing antibodies (up to 52 weeks)
Savings
Savings
Coverage Required
$25Taltz (ixekizumab)Out-of-pocket costs with copay card